• Chinese medical journal · Dec 2024

    Global, regional, and national lifetime risk of developing and dying from lung cancer in 2022: A population-based study in 185 countries.

    • Meng Li, Xin Wen, Xin Liang, Mengwen Liu, Li Zhang, and Rongshou Zheng.
    • Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
    • Chin. Med. J. 2024 Dec 20; 137 (24): 310131073101-3107.

    BackgroundLifetime cancer risk is an index that indicates the cumulative probability of cancer at some age during a person's lifetime. Nevertheless, comparative evaluations regarding the probability of developing lung cancer and dying from the disease among diverse populations at the global, regional, and national levels are scarce.MethodsLung cancer data from 185 countries were obtained from GLOBOCAN 2022, and data on any other cause of death were acquired from the United Nations. The lifetime risks of lung cancer development and death were estimated using adjustment for multiple primary cancers (AMP) method. The lung cancer risks in countries or regions worldwide were compared by region and the Human Development Index (HDI).ResultsThe global lifetime risk of developing and dying from lung cancer in 2022 was 3.49% and 2.69%, respectively. The lifetime probabilities of developing lung cancer in countries/areas with low, medium, high, and very high HDIs were 0.33%, 0.95%, 4.72%, and 5.29%, and dying from lung cancer in low, medium, high and very high HDI countries were 0.30%, 0.86%, 3.69% and 3.92%, respectively. After the age of 40 years, the remaining probability of lung cancer development and death decreased with age, leaving a residual risk of 2.00% and 1.71%, respectively, starting at 70 years.ConclusionsThe probability of developing lung cancer during one's lifetime is equivalent to 1 in 28 and 1 in 37 people suffering and dying from lung cancer. The age-related risk of developing and dying of lung cancer varies among geographic locations with different HDIs.Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,706,662 articles already indexed!

We guarantee your privacy. Your email address will not be shared.